Rindopepimut likely to be Rxed by 36% of surveyed US oncologists for GMB patients

US oncologists surveyed by advisory firm Decision Resources indicate that they would prescribe the emerging vaccine rindopepimut - Celldex Therapeutics’ CDX-110 - to 36% of their newly diagnosed glioblastoma multiforme (GBM) patients. The vaccine is still undergoing Ph III and Ph II clinical testing.

Decision Resources forecasts that rindopepimut will earn an 18% patient share in the US newly diagnosed GBM market by 2020 because only about one-third of GBM patients harbor the appropriate EGFRVIII variant targeted by rindopepimut - this factor, combined with increased competition in the GBM market, will limit the patient population eligible for the therapy.

The DecisionBase 2012 report entitled Newly Diagnosed Glioblastoma: Avastin’s Future Hangs in the Balance as Oncologists Await Phase III Data: Which Other Emerging Drugs Excite Them? also finds that surveyed US oncologists and managed care organization (MCO) pharmacy directors agree that overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in newly diagnosed GBM.